|Prof. Dr. Horst Domdey, Chairman of Supervisory Board||39,125||0|
|Dr. Yita Lee||0||0|
|Dr. Keith Manchester1)||0||0|
|Dr. Gerd Zettlmeissl||0||0|
|Dr. Frank Mathias2)||20,197||n.a.|
|Total Supervisory Board||59,322||136,089|
|Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer 3)||929,268||52,500|
|Dr. Thomas Taapken 4)||0||20,000|
|Dr. Kai Pinkernell 5)||0||33,438|
|Total Executive Board||929,268||105,938|
1) Dr. Manchester is Managing Director and Head at Life Sciences QVT Financial LP. Funds managed by QVT held 1,072,879 shares in Medigene AG according to the last voting rights notification as of 08 June 2018.
2) Dr. Frank Mathias, Member of the Supervisory Board since 15 May 2018.
3) Prof. Dr. Schendel indirectly holds 929,268 Medigene shares in her capacity as Managing Director of DJS Montana Holding GmbH. Of this total, 846,296 Medigene shares can be allocated to Prof. Dr. Schendel directly.
4) Dr. Thomas Taapken, Member of the Executive Board until 31 August 2018 (Chief Financial Officer)
5) Dr. Kai Pinkernell, Member of the Executive Board since 1 April 2018 (Chief Medical Officer & Chief Development Officer).